Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by multi-gated acquisition (MUGA)
Left ventricular ejection fraction > 50% as measured by echocardiogram or multi gated acquisition (MUGA) scan
Cardiac ejection fraction >= 50% (for HER2+ patients) as assessed by echocardiogram, multi gated acquisition scan (MUGA) scan, or cardiac magnetic resonance imaging (MRI)
Patients must not have a cardiac ejection fraction < 45% or the presence of New York Heart Association stage III or IV heart failure within 14 days prior to registration; either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) may be used to determine ejection fraction
Patients with a cardiac ejection fraction (as measured by either Multi Gated Acquisition [MUGA] or echocardiogram [EKG]) < 40%
Baseline ejection fraction ? 50% as assessed by echocardiogram or multi-gated acquisition (MUGA) scan.
Normal left ventricular ejection fraction of >= 50% estimated by multi gated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition scan (MUGA) scan
Ejection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
Ejection fraction < 40% obtained by either multi gated acquisition scan (MUGA) or echocardiogram
Normal cardiac ejection fraction (> 50%) by multi gated acquisition scan (MUGA) or echocardiogram
Adequate cardiac function defined as an ejection fraction of >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram and a corrected QT (QTc) interval of =< 450 ms for men and =< 460 ms for women
Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] or echocardiogram) < 40%
A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n> 50%.
Cardiac ejection fraction >= 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or multiple-gated acquisition (MUGA), and no clinically significant electrocardiography (ECG) findings
Adequate cardiac function defined as an ejection fraction on echocardiogram (ECHO) or multi-gated acquisition (MUGA) that is at or above the institutional normal limits
CELL PROCUREMENT: Subjects must not have left ventricular ejection fraction of < 40% (shortening fraction < 27% for pediatric subjects) as measured by echocardiogram or multi-gated acquisition (MUGA)
Ejection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scan
A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
Ejection fraction > 45% by either multi-gated acquisition scan (MUGA) scan or echocardiogram
Multi-gated acquisition (MUGA) scan or echocardiogram (ECHO) >= ejection fraction (EF) of 50%
Ejection fraction (EF) >= 50% on multi gated acquisition (MUGA) scan or echocardiogram
Has a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class ?2
Cardiac ejection fraction >= 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] scan or echocardiogram) < 40%; (Note: patients who have had prior anthracycline exposure of > 250 mg/m^2 may be eligible after discussion with the principal investigator [PI])
For children with neuroblastoma (NBL): normal ejection fraction (> 55%) documented by echocardiogram or radionuclide multi-gated acquisition (MUGA) evaluation OR normal fractional shortening (> 27%) documented by echocardiogram; for subjects with paraganglioma/ pheochromocytoma: no clinically significant cardiac dysfunction
Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) >= 50%
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45% (evaluation within 6 weeks of screening does not need to be repeated)
Cardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multi gated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptable
Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall motion is “abnormal” or “altered”)
Normal cardiac function as defined by a normal ejection fraction by multi gated acquisition scan (MUGA) or echocardiogram
Adequate cardiac function (ejection fraction [EF] > 50%) based on multi gated acquisition (MUGA) scan or 2 dimensional-echocardiogram (2D-Echo)
Patients must have normal baseline cardiac function based upon echocardiogram or gated blood pool scan (multigated acquisition scan [MUGA]) with an ejection fraction >= 50%
Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
Patients must obtain a base line echocardiogram or multi gated acquisition scan (MUGA) and require the left ventricular ejection fraction to be within normal limits (or 50% or higher)
Cardiac ejection fraction >= 50% by multiple gate acquisition (MUGA) scan and/or by echocardiogram
Cardiac dysfunction documented by an ejection fraction less than the lower limit of the facility normal by multi-gated acquisition (MUGA) scan, or less than 50% by echocardiogram
Shortening fraction > 25% by echocardiogram or ejection fraction above the institutional lower limit of normal by multi gated acquisition scan (MUGA)
Multi gated acquisition scan (MUGA) > 45% injection fraction
Left ventricular ejection fraction (EF) > 40% by echocardiogram, multi-gated acquisition (MUGA), or cardiac magnetic resonance (MR)
Cardiac function:\r\n* Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide multi gated acquisition scan (MUGA) evaluation; OR \r\n* Normal fractional shortening (>= 27%) documented by echocardiogram
Echocardiogram or multi gated acquisition (MUGA) scan demonstrating an ejection fraction >= 45%
Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%
Adequate cardiac function as defined by either of the following:            \r\n* An echocardiogram demonstrating an ejection fraction within normal limits\r\n* A multi gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limits
Patients must have a cardiac ejection fraction > 45% on two-dimensional (2D) echocardiography or multi gated acquisition scan (MUGA) obtained within 28 days of study enrollment
Poor cardiac function: left ventricular ejection fraction < 50% as determined by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) or a shortening fraction below 27%
Has a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram or multi-gated acquisition scan
Patients must have a cardiac ejection fraction >= institutional lower limit of normal (ILLN) by multi gated acquisition (MUGA) scan or 2-dimensional (D) echocardiogram (ECHO) within 42 days prior to registration
Ejection fraction of >= 45% by either multi-gated acquisition (MUGA) scan or echocardiogram (ECHO)
Subjects with major cardiac illness multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) < 50% ejection fraction (EF)
Subjects with multi gated acquisition scan (MUGA) < 50% ejection fraction (EF)
Ejection fraction >= 47% by radionuclide angiogram (multi gated acquisition scan [MUGA]); Note: the echocardiogram (or MUGA) may be done within 28 days prior to enrollment
Left ventricular ejection fraction > 45% by either multi gated acquisition scan (MUGA) scan or echocardiogram; if ejection fraction (EF) is < 50%, a cardiology consult should be placed and echocardiogram performed if not already done
Ejection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
For patients in stratum A, an echocardiogram (ECHO) or multi gated acquisition scan (MUGA) demonstrating ejection fraction (EF) > 50% is required within 28 days prior to study drug administration
Left ventricular ejection fraction of >= 40% by multi-gated acquisition (MUGA) scan or echocardiogram
Baseline ejection fraction >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram performed =< 60 days prior to registration
Subjects must have a multi gated acquisition scan (MUGA) and/or echocardiogram (ECHO) or cardiac magnetic resonance (MR); the required minimum standards include MUGA or ECHO or cardiac MR showing an ejection fraction (EF) of 40%; those with an EF 40-49% must also have a cardiologist consult and assist with management
Echocardiogram (Echo) or multi-gated acquisition scan (MUGA) with ejection fraction > 50%
Ejection fraction on echocardiogram (Echo) or multi gated acquisition scan (MUGA) > 50%
An echocardiogram (ECHO) or multiple gated acquisition (MUGA) demonstrating ejection fraction (EF) > 50%
Subjects with an evaluation of cardiac function indicating normal function on MUGA scan (multiple gated acquisition scan) or other methodology; AND
Patients must have a multi gated acquisition scan (MUGA) or echocardiogram within 90 days prior to starting treatment and the ejection fraction must be >= 45%
Normal cardiac function as demonstrated by a left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition (MUGA) scan
Ejection fraction < 50%, as determined by echocardiogram or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction >= 50% OR shortening fraction of >= 27% demonstrated on 2 dimensional (2D) echocardiogram or multi gated acquisition scan (MUGA)
Cardiac ejection fraction >= 50% as measured by echocardiogram of multiple gated acquisition scan (MUGA) scan
Ejection fraction (EF) > 50% by multi gated acquisition scan (MUGA)
Patients must have an echocardiogram or multi gated acquisition (MUGA) scan; if the ejection fraction is < 40%, the patient will not be eligible; if the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echocardiogram (echo) with a normal response to exercise
Cardiac ejection fraction >= 50% by multi-gated acquisition (MUGA) scan and/or by echocardiogram
Adequate left ventricular function with ejection fraction >= 40% by echocardiogram or multi-gated acquisition scan (MUGA) scan
Patients with a cardiac ejection fraction (as measured by either multi gated acquisition scan [MUGA] or echocardiogram) less than 40%
Measured cardiac ejection fraction > or = to 50% or the institutional lower limit of normal by echocardiogram or MUGA scan.
Ejection fraction by multi gated acquisition scan (MUGA) scan or echocardiogram >= lower limit of institutional normal
Baseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogram
Adequate cardiac function with LVEF >=50% as assessed by echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA.
Screening calculated ejection fraction greater than or equal to the institutional lower limit of normal by multiple gated acquisition (MUGA) scan or by echocardiogram (ECHO); a MUGA is preferred because of greater reproducibility
Patients must have either echocardiogram (ECHO) or multi gated acquisition scan (MUGA) with ejection fraction >= 45% within 28 days prior to registration
Cardiac ejection fraction · 40% (by either cardiac echocardiogram [ECHO] or multi gated acquisition [MUGA] scan)
Patients with prior anthracycline exposure must have a baseline multi gated acquisition scan (MUGA) or echocardiogram prior to study entry
Normal cardiac function (ejection fraction >= lower limit of normal) as determined by multi-gated acquisition scan (MUGA) or echocardiogram
Cardiac left ventricular ejection fraction > 40% by echocardiogram or multi gated acquisition scan (MUGA)
All patients must have an echo or multi gated acquisition scan (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase (CK) myoglobin binding (MB) (echo may be done at the time of stress test as a stress echo); within 6 months of starting treatment; however if the patient has received cardiotoxic chemotherapy such as Adriamycin, they must have had an echo or MUGA scan since completing this treatment
Echocardiogram or multi gated acquisition (MUGA) scan with ejection fraction within normal institution limits within 28 days of registration
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45%
A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi gated acquisition scan (MUGA) or echocardiogram
Left ventricular ejection fraction must be > 45% assessed by multi-gated acquisition scan (MUGA) scan or echocardiogram; no myocardial infarction within 6 months of transplant evaluation
Cardiac ejection fraction < 30% on multi gated acquisition scan (MUGA) scan or cardiac echocardiogram (echo) or active symptomatic coronary artery disease; patients with cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consultation as clinically indicated
Subjects with major cardiac illness multi-gated acquisition scan (MUGA) < 50% ejection fraction (EF)
Estimated cardiac ejection fraction >= 50% by echocardiogram or multi gated acquisition scan (MUGA)
Ejection fraction >= lower limit of normal (LLN) by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)